These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 1966946)

  • 21. Phenotypic and functional analysis of peripheral blood mononuclear cells in generalised aggressive and chronic periodontitis patients.
    Emingil G; Karaarslan F; Keskinoğlu A; Coker I; Atilla G
    J Int Acad Periodontol; 2001 Oct; 3(4):87-94. PubMed ID: 12666947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating T and B lymphocytes in progressive systemic sclerosis.
    de Jesus DG; Clancy RL
    J Rheumatol; 1975 Sep; 2(3):336-9. PubMed ID: 1081143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis.
    Famularo G; Procopio A; Giacomelli R; Danese C; Sacchetti S; Perego MA; Santoni A; Tonietti G
    Clin Exp Immunol; 1990 Sep; 81(3):368-72. PubMed ID: 2397608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Circulating CD8 as an indicator of inflammatory rheumatic disease].
    Becker H; Paul E; Schaum S; Renelt M; Federlin K
    Immun Infekt; 1992 Feb; 20(1):6-9. PubMed ID: 1563757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble CD4 and CD8 molecules in patients with systemic sclerosis.
    Tokano Y; Kaneko H; Obara T; Hashimoto H; Okumura K; Hirose S
    Clin Rheumatol; 1993 Dec; 12(4):490-3. PubMed ID: 8124911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble immunologic products in scleroderma sera.
    Kahaleh MB
    Clin Immunol Immunopathol; 1991 Jan; 58(1):139-44. PubMed ID: 1898505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease.
    Giacomelli R; Cipriani P; Lattanzio R; Di Franco M; Locanto M; Parzanese I; Passacantando A; Ciocci A; Tonietti G
    Clin Exp Immunol; 1997 Apr; 108(1):42-6. PubMed ID: 9097909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma.
    Zillikens D; Blum C; Dummer R; Hartmann AA; Burg G
    Dermatology; 1992; 184(3):233-4. PubMed ID: 1392125
    [No Abstract]   [Full Text] [Related]  

  • 29. [Immunologic similarities observed in the course of multiple sclerosis and systemic scleroderma].
    Czernicki J; Niedworok J; Onisk Z; Tchórzewski H
    Pol Tyg Lek; 1978 Feb; 33(9):337-40. PubMed ID: 652647
    [No Abstract]   [Full Text] [Related]  

  • 30. Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.
    Airò P; Bettinzioli M; Gorla R; Cattaneo R
    Ann Rheum Dis; 1991 Apr; 50(4):270-1. PubMed ID: 2029213
    [No Abstract]   [Full Text] [Related]  

  • 31. Lowered angiogeneic capability of peripheral blood lymphocytes in progressive systemic sclerosis (scleroderma).
    Kaminski MJ; Majewski S; Jablonska S; Pawinska M
    J Invest Dermatol; 1984 Mar; 82(3):239-43. PubMed ID: 6199433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble CD4 and CD8 in serum from patients with localized scleroderma.
    Sato S; Fujimoto M; Kikuchi K; Ihn H; Tamaki K; Takehara K
    Arch Dermatol Res; 1996 Jun; 288(7):358-62. PubMed ID: 8818182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.
    Spronk PE; ter Borg EJ; Huitema MG; Limburg PC; Kallenberg CG
    Ann Rheum Dis; 1994 Apr; 53(4):235-9. PubMed ID: 8203951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in Crohn's disease, celiac disease, and systemic lupus erythematosus.
    Srivastava MD; Rossi TM; Lebenthal E
    Res Commun Mol Pathol Pharmacol; 1995 Jan; 87(1):21-6. PubMed ID: 7735726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus.
    Linker-Israeli M; Hyun S; Ozeri-Chen T; Wallace DJ; Banks K; Klinenberg JR
    J Immunol; 1994 Mar; 152(6):3158-67. PubMed ID: 8144910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum soluble interleukin 2 receptor alpha and soluble CD8 levels in patients with gynecological malignancies undergoing radiotherapy.
    Frydecka I; Rusiecka M; Kuliczkowski K; Kornafel J
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):123-6. PubMed ID: 8915516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble CD8 antigen in systemic sclerosis.
    Famularo G; Giacomelli R; Sacchetti S; Danese C; Luciani AM; Perego MA; Tonietti G
    J Clin Lab Immunol; 1990 Jul; 32(3):109-12. PubMed ID: 1966946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population.
    Pantaleo G; Koenig S; Baseler M; Lane HC; Fauci AS
    J Immunol; 1990 Mar; 144(5):1696-704. PubMed ID: 2137842
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.